# Avelumab in Refractory Testicular Germ Cell Cancer.

> **NCT03403777** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute, Slovakia** · enrollment: 8 (actual)

## Conditions studied

- Testicular Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neoplasms
- Testicular Diseases
- Gonadal Disorders
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03403777
- **Lead sponsor:** National Cancer Institute, Slovakia
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-15
- **Primary completion:** 2019-02-28
- **Final completion:** 2019-02-28
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03403777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03403777, "Avelumab in Refractory Testicular Germ Cell Cancer.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03403777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*